Every year, World Toilet Day is observed to raise awareness about the global sanitation crisis and encourage action to solve it. The goal set by the United Nation is to achieve safe toilets for all by 2023, as a part of their Sustainable Development Goals.
The UN also states that 3.5 billion people live without proper sanitation and many children also lose their lives due to poor sanitation and unsafe water. This is why World Toilet Day is observed to raise awareness on this issue.
This year, the theme for World Toilet Day 2024 is "Toilets - A Place for Peace'. This focuses on the growing threat to sanitation that is caused by conflict, climate change, disaster and neglect. When there is a threat to using toilets, it can lead to many health risks.
Not using toilets for too long may lead to Urinary Tract Infection or UTI. For many who do not have access to clean toilets do not drink enough liquid or hold pee for too long. Doctors suggest that holding in pee for too long can cause bacteria to multiply and lead to UTI. By not drinking enough water, your bladder fails to tell the body to pee often, and can cause the bacteria to spread through the urinary tract, which can lead to infection.
Holding in pee for too long can also cause your bladder to stretch, making it difficult or even impossible for the bladder to contract and release pee normally. It can also damage your pelvic floor muscles or could lead to kidney stones.
To prevent such conditions, it is important that everyone has access to clean and safe toilets. In terms of history, the day was established in 2001, by the World Toilet Organization (WTO), which was founded by Jack Sim. However, it was officially recognised by the UN in 2013. The Government of Singapore worked with WTO to create the first UN resolution called Sanitation for All.
India too promotes safe and hygiene toilet through its Swachh Bharat Yojna.
Credit: AI
A compound best known for its psychedelic effects may have potential in protecting cancer patients from nerve damage caused by chemotherapy.
Researchers at the University of Texas MD Anderson Cancer Center found that psilocybin, the active psychedelic compound in 'magic mushrooms,' prevented peripheral neuropathy induced by chemotherapy in several preclinical models. The findings were published in Science recently.
It can cause burning or shooting pain, numbness, tingling, increased sensitivity to cold and loss of sensation, especially in the limbs. In some cases, the nerve damage can persist long after chemotherapy ends and may even become irreversible.
Currently, there are not a lot of options for preventing this type of nerve injury, making researchers explore other approaches that could protect nerves before chemotherapy causes damage.
Also read: Bladder Cancer Detection May Get Faster & Easier: New Urine Test Detects 92% Of Cases
In the new study, researchers tested psilocybin in multiple models involving chemotherapy drugs including cisplatin, paclitaxel and docetaxel.
They found that as few as two doses of psilocybin given before chemotherapy prevented several signs of peripheral neuropathy.
Treated models retained normal touch sensation, showed less sensitivity to cold and maintained sensory nerve endings, even after repeated chemotherapy sessions.
The researchers also found no evidence that psilocybin interfered with chemotherapy's ability to attack tumours in these models.
Also read: PM2.5 and Cancer Risk: Practical Ways to Protect Yourself in India’s Polluted Cities
According to the researchers, the answer may lie in the way nerve cells transport mitochondria, the components responsible for producing cellular energy.
Chemotherapy can disrupt this transport system, leaving nerve endings without enough energy and making them vulnerable to damage.
Psilocybin appeared to preserve mitochondrial movement through a pathway involving the serotonin 5-HT2A receptor. When researchers blocked this pathway, the protective effect disappeared.
Additionally, a non-hallucinogenic compound that activates the same receptor produced similar nerve-protective effects in the models. This suggests that the potential benefit may not depend on psilocybin's psychedelic experience itself.
Dr Moran Amit, the study's co-lead, said, "There is an urgent need for treatments that can prevent nerve injury without interfering with life-saving chemotherapy. He said the findings offer insight into protecting nerves before damage becomes persistent."
The study was conducted using laboratory and animal models, so it is not yet known whether the same protective effect will occur in people who are undergoing chemotherapy.
Researchers are now moving toward a Phase II clinical trial, known as NeuroGuard, to test whether psilocybin can prevent or reduce CIPN in people receiving chemotherapy for breast, colorectal or head and neck cancers. The trial is listed by the US National Cancer Institute as an approved Phase II study.
The trial will also examine whether preventing nerve damage could help patients tolerate their cancer treatment better and maintain quality of life.
Credit: AI
A problem in the heart may not just be confined to the heart. According to new guidelines, heart and kidney health may be more closely linked to each other than we realise. Heart disease can increase the strain on the kidney, creating a cycle that may raise the risk of serious complications.
New guidelines from the European Society of Cardiology (ESC), developed in collaboration with the European Renal Association (ERA), are emphasising upon monitoring kidney health in people with cardiovascular disease more closely.
The recommendations, published in the European Heart Journal, are the ESC's first dedicated guidelines covering cardiovascular disease and chronic kidney disease together.
The heart pumps blood throughout the body, while the kidneys filter waste and excess fluid from the blood. Because the two organs are closely linked through blood flow, fluid balance and blood pressure, dysfunction in one can place additional stress on the other.
According to the ESC, chronic kidney disease can accelerate cardiovascular disease, while cardiovascular disease can also worsen kidney problems.
This can contribute to complications including heart failure, stroke, abnormal heart rhythms, and progression to kidney failure requiring dialysis.
The European Society of Cardiology estimates that around 100 million people in Europe have chronic kidney disease, which itself substantially increases the risk of cardiovascular disease.
Associate Professor Kevin Damman of University Medical Centre Groningen, who chaired the guideline task force, said, "The disability and lifetime lost to each disease are profound, but CKD can accelerate CVD and vice versa, resulting in cardiovascular events and the need for dialysis much earlier in life."
He added, "The good news is that there have been major advances over the last few years, which mean there are now several simple treatments that can substantially lower the risk of both cardiovascular and kidney complications."
One of the biggest changes is an emphasis on earlier kidney screening in people with cardiovascular disease. The guidelines recommend assessing kidney health using two tests:
eGFR, calculated from a blood creatinine test, which estimates how well the kidneys are filtering blood.
Urine albumin-to-creatinine ratio (UACR), which checks albumin leaking into the urine, a sign of kidney damage.
The ESC recommends active screening, risk assessment and treatment of CKD among people with cardiovascular disease.
This is crucial as kidney disease can go unnoticed for years, especially when symptoms are absent. Detecting it earlier can help doctors identify people at higher cardiovascular risk and adjust treatment accordingly.
Also read: From Pickles to Papad: Which Everyday Indian Foods Could Be Worth Rethinking for Cancer Prevention?
The new guidelines also stress that the presence of kidney disease should not unnecessarily delay appropriate cardiovascular treatment.
Instead, doctors may need to modify treatment and monitor patients more closely due to the additional kidney-related risks.
The guideline framework is summarised by STAMP: Screen, Triage and Address CKD Risk, Modify CVD management, and Plan health services.
The recommendations cover a wide range of cardiovascular conditions, including coronary disease, heart failure, arrhythmias, stroke, and peripheral arterial disease.
Credit: AI
British-Nigerian businessman and social media influencer Igho “Tiny” Ubiribo, 43, died after undergoing a cosmetic penis enlargement procedure in Bangkok, Thailand.
According to findings from a UK coroner’s inquest, Ubiribo, who was also known as Denisi or Ego, reportedly underwent the procedure on March 5, 2026, while travelling with his wife. The treatment involved injections containing hyaluronic acid and lidocaine.
According to reports on the inquest, Ubiribo developed chest pain and repeatedly lost consciousness later that day while receiving a massage.
He was taken to Sukhumvit Hospital in Bangkok, where his condition deteriorated rapidly. Doctors reportedly attempted CPR for more than 100 minutes, but he died before a CT scan could be completed.
A post-mortem examination in the UK subsequently found that he had suffered a pulmonary embolism, a potentially life-threatening blockage of blood flow in the lungs.
The coroner’s findings reportedly linked the fatal embolism to the substances injected during the cosmetic procedure. Reports say material consistent with the filler was found in the lungs.
Also read: Lindsay Clancy Trial: What Postpartum Psychosis Really Looks Like, From A Survivor
A pulmonary embolism occurs when a blood vessel supplying the lungs becomes blocked, most commonly by a blood clot that has travelled from another part of the body.
It can cause sudden chest pain, shortness of breath, rapid heartbeat, dizziness, or fainting and can become fatal if the blockage is severe.
In Ubiribo's case, the coroner’s findings linked the embolism to material associated with the cosmetic injection rather than describing a conventional blood clot travelling from the legs, which is unusual.
Complications can include infection, swelling, tissue damage, deformity, nodules, and vascular complications. If an injected substance enters a blood vessel, there can be potentially serious consequences.
The risks can also depend on the substance used, injection technique, the setting in which the procedure is performed, and the medical expertise and competence of the person administering it.
Ubiribo’s case does not mean that every penile filler procedure causes pulmonary embolism, but it indicates that cosmetic procedures are not risk-free simply because they are elective.
The American Urological Association and Urology Care Foundation have previously stated that subcutaneous fat injection for increasing penile girth has not been shown to be safe or effective.
Ubiribo’s death has now renewed attention on the risks associated with cosmetic penile augmentation, particularly when procedures are undertaken abroad.
© $2026 Times Horizon Private Limited